Hims & Hers Health (HIMS.US) rose over 5% to a new record high
Wednesday, Nov 27, 2024 11:00 am ET
1min read Hims & Hers Health (HIMS.US) rose over 5% on Wednesday, setting a new record high of US$32.23. On Monday, Hunterbrook Media, an institution that "targets short-seller Citron", released a report stating that Trump nominated Marty Makary as the head of the US Food and Drug Administration (FDA), and Hims & Hers may benefit greatly from this nomination, as Makary is a senior executive of Sesame Inc., which is a startup that sells the same combination GLP-1 weight loss drug as Hims & Hers.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.